英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Aimovig (erenumab) available on NHS in England and Wales
    The National Institute for Health and Care Excellence (NICE) has confirmed that erenumab can be prescribed for migraine prevention free of charge on the National Health Service (NHS) in England and Wales Physicians may consider erenumab 140 mg as an option for migraine prevention in adults who have four or more migraine days a month
  • Erenumab | CGRP Education Research Forum
    In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults Approval was supported by data including results of the Phase 3 STRIVE and ARISE studies in episodic migraine and the results of a large Phase 2 study in chronic migraine Erenumab was further investigated
  • Slides | CGRP Education Research Forum
    Slides Our slide decks bring together extensive clinical trial data supporting the efficacy and safety of the CGRP monoclonal antibodies, erenumab, fremanezumab, galcanezumab and eptinezumab, and the CGRP receptor antagonists (gepants), ubrogepant, rimegepant and atogepant
  • Retrospective analysis supports erenumab in trigeminal neuralgia
    Improved pain scores and mood have been reported by patients with trigeminal neuralgia (TN) who were treated with erenumab Nine out of 10 patients diagnosed with TN and treated with erenumab for six months reported improvement in pain severity according to a numeric pain rating scale (NPRS) from 0 to 10, and in global mood
  • Peter Goadsby | CGRP Education Research Forum
    Erenumab (previously known as AMG 334), a calcitonin gene-related peptide (CGRP) receptor antibody, not only reduced monthly migraine days compared with placebo, but also showed no differences for serious or nonserious adverse events versus placebo groups in these two trials According to CGRP Forum Co-Editor Professor Peter Goadsby, who presented results from the STRIVE trial1, the lack of
  • Reassuring safety of anti-CGRP therapies in pregnancy but ongoing . . .
    Reference Noseda R, Bedussi F, Gobbi C et al Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database Cephalalgia 2021 Jan 12; Online ahead of print
  • PowerPoint Presentation
    Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
  • Migraine care in Brazil: the role of anti-CGRP therapies
    Migraine care in Brazil: the role of anti-CGRP therapies is a new slide deck summarising clinical trial and real world data, with links to key references Although focusing on use of CGRP monoclonal antibodies in Brazil, it includes an update of key clinical results with erenumab, fremanezumab, galcanezumab and eptinezumab that is relevant to clinicians


















中文字典-英文字典  2005-2009